Tag Archives: PDAC

October, 2018

19 October
BioLineRx Presents Top-Line Results from its Mid-Stage Study in Pancreatic Cancer at ESMO

Tel Aviv, Israel, October 19, 2018 – BioLineRx Ltd. (NASDAQ/TASE:BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced top-line results from the dual combination arm of the Phase 2a COMBAT/KEYNOTE-202 study, evaluating patients with metastatic pancreatic adenocarcinoma (PDAC) treated with BL-8040 in combination with KEYTRUDA® (pembrolizumab), an …
Share

29 March
Protein Identified as Potential Druggable Target for Pancreatic Cancer

A protein known as arginine methyltransferase 1 (PRMT1) may be a potential therapeutic target for pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer, and one of the most deadliest with a less than 10 percent, five-year survival rate. PRMT1 is involved in a number of genetic processes …
Share

2 December
Boehringer Ingelheim Partners with MD Anderson to Identify New Approaches to Treat Pancreatic Cancer

RIDGEFIELD, Conn. and HOUSTON, Texas, Dec. 2, 2015 /PRNewswire/ — Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced a collaboration focused on developing innovative medicines for pancreatic ductal adenocarcinoma (PDAC). The new collaboration combines MD Anderson’s unique understanding of potential drivers of PDAC with Boehringer Ingelheim’s …
Share